Synonyms:
Status: Phase 3
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: 3062P60MH9

Pharmacology

Action Mechanism of Action Reference
INHIBITOR CD22 inhibitor PubMed PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lupus Erythematosus, Systemic 3 D008180 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 D054198 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Lymphoma, Non-Hodgkin 2 D008228 ClinicalTrials
Waldenstrom Macroglobulinemia 2 D008258 ClinicalTrials
Leukemia, Biphenotypic, Acute 2 D015456 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 1 D016403 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 205923-57-5
ChEMBL CHEMBL2108404
FDA SRS 3062P60MH9
Guide to Pharmacology 8088